12 completed, 7 terminated, 5 recruiting, 4 withdrawn. 34 Phase 2, 4 Phase 3, 3 Phase 1.
Follow Primary Sclerosing Cholangitis: new trials by email Literature Review of Primary Sclerosing Cholangitis trials Research Report on Primary Sclerosing Cholangitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus Nemolizumab-ilto - Chronic Hepatic Pruritus, Cholestatic Liver Disease | Phase 2 | Not yet recruiting | Mayo Clinic | 15 | 2026-11-01 | 2026-09-28 |
| A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis Aramchol meglumine - Primary Sclerosing Cholangitis | Phase 2 | Withdrawn | Galmed Pharmaceuticals Ltd | 2025-06-01 | 2025-06-12 | |
| Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA) - Primary Sclerosing Cholangitis, Liver Transplant, Complications | Phase 2 | Recruiting | Mayo Clinic | 80 | 2025-04-15 | 2026-07-17 |
| A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis. aldafermin, Placebo - Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | Withdrawn | NGM Biopharmaceuticals, Inc | 2024-10-21 | 2025-05-07 | |
| The Effects of Bromelain Supplement in Patients With Ulcerative Colitis Bromlein, Placebo - Ulcerative Colitis, Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | Completed | National Nutrition and Food Technology Institute | 52 | 2024-04-20 | 2026-10-27 |
| FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis Faecal Microbiota Transplant, FMT Placebo - Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases | Phase 2 | Recruiting | University of Birmingham | 58 | 2024-03-27 | 2026-09-24 |
| Detoxification of the Liver In PSC (Dolphin) BRS201, Placebo - Primary Sclerosing Cholangitis | Phase 2 | Recruiting | Brigham and Women's Hospital | 28 | 2023-12-12 | 2026-07-21 |
| CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis) CS0159 - Primary Sclerosing Cholangitis | Phase 2 | Active not recruiting | Cascade Pharmaceuticals, Inc | 50 | 2023-08-07 | 2026-03-13 |
| Vancomycin in Primary Sclerosing Cholangitis in Italy Oral Vancomycin, Placebo - Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder | Phase 2 | Recruiting | University of Milano Bicocca | 84 | 2023-06-15 | 2025-07-25 |
| Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis. Hymecromone - Primary Sclerosing Cholangitis | Phase 2 | Recruiting | Aparna Goel | 24 | 2023-05-10 | 2025-06-13 |
| Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis Ritivixibat - Primary Sclerosing Cholangitis | Phase 2 | Terminated | Albireo, an Ipsen Company | 18 | 2023-01-09 | 2026-05-04 |
| A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. Elafibranor 80 mg, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg - Primary Sclerosing Cholangitis | Phase 2 | Active not recruiting | Ipsen | 68 | 2022-12-29 | 2026-10-23 |
| Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis HK-660S, Placebo - Primary Sclerosing Cholangitis | Phase 2 | Completed | CuromeBiosciences | 23 | 2021-10-28 | 2023-07-27 |
| A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC) HTD1801, Ursodeoxycholic Acid - Primary Sclerosing Cholangitis, Cholangitis | Phase 2 | Withdrawn | HighTide Therapeutics (Hong Kong) Limited | 2021-03-01 | 2026-08-12 | |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) Volixibat, Placebo - Primary Sclerosing Cholangitis | Phase 2 | Active not recruiting | Mirum Pharmaceuticals, Inc. | 182 | 2020-12-18 | 2026-10-19 |
| CM-101 in PSC Patients -The SPRING Study Anti-human CCL24 monoclonal antibody (CM-101), Placebo - Primary Sclerosing Cholangitis | Phase 2 | Completed | ChemomAb Ltd. | 77 | 2020-10-01 | 2026-07-02 |
| Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC) PLN-74809, Placebo - Primary Sclerosing Cholangitis | Phase 2 | Completed | Pliant Therapeutics, Inc. | 121 | 2020-07-27 | 2026-01-23 |
| Vancomycin for Primary Sclerosing Cholangitis Vancomycin, Placebo - Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | Terminated | Elizabeth Carey | 102 | 2020-01-23 | 2026-10-21 |
| A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC Seladelpar, Placebo to match Seladelpar - Primary Sclerosing Cholangitis | Phase 2 | Terminated | Gilead Sciences | 1 | 2019-11-12 | 2025-01-16 |
| Vidofludimus Calcium for Primary Sclerosing Cholangitis Vidofludimus calcium - Primary Sclerosing Cholangitis | Phase 2 | Completed | Elizabeth Carey | 18 | 2019-06-17 | 2022-10-17 |
Showing 20 of 34. Sign in to see all of them.
Cholangitis, Sclerosing (34) · Cholangitis (3) · Digestive System Diseases (3) · Bile Duct Diseases (2) · Biliary Tract Diseases (2) · Cholestasis (2) · Inflammatory Bowel Diseases (2) · Colitis, Ulcerative (1) · Liver Cirrhosis, Biliary (1) · Pruritus (1)
Bile Duct Diseases (32) · Biliary Tract Diseases (32) · Cholangitis (31) · Digestive System Diseases (31) · Gastroenteritis (3) · Gastrointestinal Diseases (3) · Intestinal Diseases (3) · Pathological Conditions, Signs and Symptoms (2) · Cholestasis, Intrahepatic (1) · Colitis (1) · Colonic Diseases (1) · Fibrosis (1) · Inflammatory Bowel Diseases (1) · Liver Cirrhosis (1) · Liver Diseases (1)
Fenofibrate (2) · Ursodeoxycholic Acid (2) · Vancomycin (2) · aldafermin (2) · (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (1) · Blood Specimen Collection (1) · Curcumin (1) · Hymecromone (1) · Mitomycin (1) · Pharmaceutical Preparations (1) · Saline Solution (1) · Sulfasalazine (1) · Thalidomide (1) · cenicriviroc (1)
Mayo Clinic (4) · Brigham and Women's Hospital (2) · Elizabeth Carey (2) · Gilead Sciences (2) · NGM Biopharmaceuticals, Inc (2) · University of Birmingham (2) · Albireo, an Ipsen Company (1) · Aparna Goel (1) · Cascade Pharmaceuticals, Inc (1) · ChemomAb Ltd. (1) · CuromeBiosciences (1) · Dr. Falk Pharma GmbH (1) · Durect (1) · Fuzhou General Hospital (1) · Galmed Pharmaceuticals Ltd (1)
United States (22) · United Kingdom (8) · Canada (6) · Germany (5) · France (4) · Italy (4) · Spain (4) · Austria (3) · Netherlands (3) · Australia (2) · Belgium (2) · Israel (2) · Poland (2) · Argentina (1) · Brazil (1)
Elizabeth Carey, MD (2) · Alastair Smith, MD (1) · Aparna Goel, MD (1) · Arun Sanyal, MD (1) · Azita Hekmatdoost, MD, PhD (1) · Channa Jayasekera (1) · Cynthia Levy, MD (1) · Do-hyun Park (1) · J.P. Nicandro (1) · Jason Sluzevich, MD (1) · Joshua A Korzenik, MD (1) · Joshua R Korzenik, MD (1)
PMID 19585548, PMID 28529147, PMID 28674140, PMID 30661255, PMID 33681680, PMID 33898959, PMID 37055910, PMID 39762111, PMID 40350321, PMID 41016442, PMID 41513411, PMID 42489629
2014 (1), 2015 (1), 2016 (1), 2019 (1), 2023 (1), R01DK056924 (1)